A Registry Study on Primary/idiopathic Triglyceride Deposit Cardiomyovasculopathy

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan193 enrolled

Overview

The objective of this study is to construct a registry; in order to understand the onset status of triglyceride deposit cardiomyovasculopathy (TGCV) in Japan with patients' background and natural history of the disease, and to explore disease-specific prognostic factors.

Study Type

OBSERVATIONAL

Enrollment

193

Conditions

Triglyceride Deposit Cardiomyovasculopathy

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients who have been conﬁrmed as TGCV based on the diagnostic criteria for TGCV Exclusion Criteria: * The patients who refused to participate in the study by opt-out

Locations (7)

Aichi Medical University

Nagakute, Aichi-ken, Japan

Nagoya University

Nagoya, Aichi-ken, Japan

Chiba University Graduate School of Medicine

Chiba, Chiba, Japan

Kyushu University

Fukuoka, Fukuoka, Japan

Outcomes

Primary Outcomes

The period between the date of TGCV diagnosis and the date of death due to any cause

The period is from the date of diagnosis of TGCV to the date of death due to any cause. Survival and lost follow-up cases will be censored on the final confirmation date of survival.

Time frame: 10 years

Secondary Outcomes

Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: Washout rate of BMIPP (%)

Time frame: 10 years

Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: LVEF (%) (UCG or QGS)

Time frame: 10 years

Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: Any cardiovascular events

Time frame: 10 years

Presence (date of occurrence or treatment) or absence of various events

To measure the period from the date of diagnosis of TGCV to the date the following event occurs: non-fatal myocardial infarction by the outcome assessment, non-fatal stroke, hospitalization for heart failure, CABG, PCI, TVR, pacemaker/ICD implantation, CRT, VAD, acute coronary syndrome requiring hospitalization, hospitalization/device activation/heart transplantation due to fatal arrhythmia. However, surgery scheduled at the time of diagnosis will not be treated as an event.

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.